Loading…
← CockpitCompetitor Analysis › 603193.SS Runben Biotechnology Co Ltd. Class AOpen in the cockpit ↗

Runben Biotechnology Co Ltd. Class A603193.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Household/Personal Care

Chinese household products company known for insect-repellent (mosquito patches/sprays) and baby-care items, sold via e-commerce.

≈ A Chinese e-commerce-led household/insect-repellent and baby-care brandMomentum laggard 15
Mkt cap
$940M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$10.8M
20-day average traded
Fwd P/E
18.9×
forward earnings
ROIC−WACC
+26.3 pp
WACC 7.1%
Hurdle
-27 pp
Req g minus delivered
Next earnings
117 days
3 Mar 2027
Close · CNYCN¥17.41
1D-1.2%
1W+3.3%
1M-10.4%
3M-20.2%
6M-33.0%
YTD-28.1%
1Y-34.4%
ATR %3.5%
52w lowhigh35.0% off high

What Runben Biotechnology does

Chinese household products company known for insect-repellent (mosquito patches/sprays) and baby-care items, sold via e-commerce.

In one line: A Chinese e-commerce-led household/insect-repellent and baby-care brand.

Products and services

  • Insect-repellent products
  • Baby-care toiletries
  • Essential-oil/household fragrance products

Customers

  • Online consumers (Tmall/JD/Douyin)
  • Parents/families

Where it sits in the supply chain

  • Consumer staples
  • Household/personal care
  • Insect repellent, baby care toiletries

What could go right

  • E-commerce category growth in baby/household care

What could go wrong

  • Seasonal demand (insect repellent)
  • Category competition

Moat: narrow (brand, distribution). Recognized e-commerce brand niche in insect repellent and baby-care categories.

Headquarters: Guangzhou, China · Employees: 1,018

Named competitors

  • Johnson's Baby (Kenvue) private or unlisted

Runben Biotechnology at a glance

Size Runben Biotechnology (603193.SS) is a China Consumer Staples company (Household/Personal Care) with a market value of $940M, the 2425th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.41 on 6 Nov 2026.

Performance Over six months the shares fell 33.0%, against +1.4% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 12.9% over the last twelve months (peer median +10.2%); the operating margin is 21.4% (peer median 8.9%).

Valuation It trades at 18.9× forward earnings against a peer median of 19.4× (10th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 26.3 points above its cost of capital (7.1% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 103603193.SS 65
Six months, rebased to 100: Runben Biotechnology against the median of its 20 peers (local-currency closes).

Runben Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.71BCN¥1.53BCN¥1.31BCN¥1.03BCN¥850M
Revenue growth—+17%+27%+21%—
Gross profitCN¥1.04BCN¥879MCN¥746MCN¥565MCN¥449M
EBITDAn/aCN¥350MCN¥329MCN¥265MCN¥197M
Net incomeCN¥349MCN¥315MCN¥300MCN¥226MCN¥160M
Free cash flowCN¥239MCN¥210MCN¥224MCN¥244MCN¥127M
Capital expenditureCN¥102MCN¥87.8MCN¥74.2MCN¥13.7MCN¥40.7M
Total debtCN¥355,961CN¥1.42MCN¥2.78MCN¥4.00MCN¥7.91M

Quarterly statements and history in the cockpit →

Runben Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%00132830110849283007402657GALAXYSURF241710JYOTHYLAB6050092145EPC4836504919603983ICOSPZC301371BAJAJCON603193.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Runben Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%10×20×30×40×00132830110849283007402657GALAXYSURF241710JYOTHYLAB6050092145EPC4836504919603983003006ICOS002790PZC301371BAJAJCON603193.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Runben Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%00132849283007402657GALAXYSURF241710JYOTHYLAB6050092145EPC4836504919003006002790PZC301371BAJAJCON603193.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Runben Biotechnology is the large dot.

Runben Biotechnology competitors and peer comparison

How Runben Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Runben Biotechnology against its 20 peers (data as of 6 Nov 2026)
Measure603193.SSPeer medianRank in peer set
1-month return-10.4%+0.3%8th lowest of 21
6-month return-33.0%+1.4%4th lowest of 21
Distance from 52-week high-35.0%-31.6%8th lowest of 21
Revenue growth (TTM)+12.9%+10.2%10th highest of 21
Operating margin21.4%8.9%2nd highest of 21
Forward P/E18.9×19.4×10th cheapest of 21
Growth the price implies (Req g, 7 yrs)1.7%4.4%8th least demanding of 19
Growth delivered (Del g)+28.4%+8.5%3rd highest of 19
Hurdle (Req g minus delivered)-26.7 pp-4.7 pp4th least demanding of 19
ROIC minus cost of capital+26.3 pp+6.3 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Runben Biotechnology 603193.SSChina$940M-33%+13%21%18.9×1.7%+28.4%
Dencare (Chongqing) Oral Care 001328.SZChina$944M+15%+10%11%28.9×4.3%+10.8%
Tongling Jieya Biologic Technology 301108.SZChina$961M+47%+54%7%54.0×n/an/a
Noevir 4928.TJapan$977M+3%+1%16%19.4×-4.8%+4.5%
SYoung 300740.SZChina$1.00B-37%+14%3%39.6×18.1%+6.1%
Shanghai Forest Cabin Cosmetics 2657.HKHong Kong$1.06B0%+74%18%12.1×11.5%+49.0%
Galaxy Surfactants GALAXYSURF.NSIndia$819M+13%+30%9%18.6×18.0%+13.7%
Cosmecca Korea 241710.KSSouth Korea$798M+25%+44%13%14.4×-5.9%+13.6%
Jyothy Labs JYOTHYLAB.NSIndia$773M-23%+5%8%30.9×35.0%+8.9%
Hangzhou Haoyue Personal Care 605009.SSChina$750M-19%+10%6%17.7×4.7%+7.7%
Shanghai Chicmax Cosmetics 2145.HKHong Kong$1.22B-52%+23%8%15.0×-5.9%+21.2%
Edgewell Personal Care EPCUnited States$1.29B+32%-7%6%12.4×4.1%+2.7%
d'Alba Global 483650.KSSouth Korea$1.32B-37%+55%21%13.6×-2.2%+53.0%
Milbon 4919.TJapan$669M+30%+6%13%22.9×-3.1%+8.2%
Guangdong Marubi Biotechnology 603983.SSChina$1.45B-4%-6%2%37.0×n/an/a
Chongqing Baiya Sanitary Products 003006.SZChina$1.49B+25%0%3%41.2×30.6%+22.8%
Intercos ICOS.MIItaly$1.50B+16%-5%9%19.5×4.5%+11.5%
AMOREPACIFIC 002790.KSSouth Korea$1.55B-3%+9%9%8.4×-17.9%-1.3%
PZ Cussons PZC.LUnited Kingdom$566M+30%+5%11%13.3×-1.7%-2.1%
Harbin Fuerjia Technology 301371.SZChina$1.58B-30%+28%20%22.5×8.7%+3.6%
Bajaj Consumer Care BAJAJCON.NSIndia$551M-24%+29%22%19.6×14.6%+5.0%

Questions

Who are Runben Biotechnology's main competitors?
Named competitors: Johnson's Baby (Kenvue) (private or unlisted). The cockpit's measured peer set (industry) also includes Dencare (Chongqing) Oral Care (001328.SZ), Tongling Jieya Biologic Technology (301108.SZ), Noevir (4928.T), SYoung (300740.SZ), Shanghai Forest Cabin Cosmetics (2657.HK), Galaxy Surfactants (GALAXYSURF.NS).
Is Runben Biotechnology expensive compared with its peers?
On forward p/e it trades at 18.9× against a peer median of 19.4×, 10th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has Runben Biotechnology stock performed?
Over six months to 6 Nov 2026 the shares returned -33.0% against +1.4% for the median peer; over one year -34.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.